The IBRI has a proven ability to overcome organizational barriers to facilitate complex, multi-organizational projects. Our researchers are actively leading inquiry and analysis in regenerative medicine, single cell bioanalytics, and advanced data science.
Better Predicting Safe Molecules
The high cost of developing any molecule for use as a new drug or agricultural product makes accurate early assessment of the safety of those molecules critical. More accurate early predictions about the safety of a molecule can potentially save companies time and millions in development costs with a “fail fast” model, while focusing research activities on molecules that are more likely to meet regulatory requirements and societal expectations.
Two of Indiana’s global life sciences companies, Dow AgroSciences and Eli Lilly and Company, have both independently developed analytic pipelines to assist their scientists in interpreting the safety assessment data to determine the potential risk of new molecules. The Indiana Biosciences Research Institute (IBRI) collaborated with these companies to take their independently-developed analytic pipelines and develop a common platform to identify and quantify potential compound toxicity from the transcriptomic data. This platform uses current industrial experience and decision-making to improve adoption by the larger research and regulatory communities of these newer methods to rapidly assess compound toxicity and biological rationales. It also enables multiple standard informatics methods to be run consistently and compared across existing public data sets.
In these early discovery experiments, detailing the disruptions of the biological pathways by these compounds allows scientists to better predict how the study results may translate to other human or environmental impacts.
The IBRI Diabetes Center, led by Dr. Robert Considine, includes his lab, the Considine Lab, and the Lilly Diabetes Center of Excellence (LDCE).
Instructing Proper Pancreas Development
Why does the pancreas remain healthy in some people and become diseased in others? It’s a complex question that we are trying to answer by deconstructing the biological pathways that direct cell development, differentiation and regeneration in the pancreas. By understanding the role different genes and proteins, especially enzymes, play in the development of the pancreas, we will be able to identify potential drug targets that could be used to better treat or possibly reverse diabetes.